Journal of Medicinal Chemistry · 2019 · 39 citations · 18 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsEnzyme InhibitionLigand BindingPotency OptimizationStructure-activity Relationship AnalysisHistone Acetyltransferase InhibitionHistone AcetyltransferasesMedicinal Chemistry ApplicationsStructure - Activity Relationship OptimizationStructure-activity Relationship ModelingTranscription Inhibitors
A high-throughput screen for inhibitors of the histone acetyltransferase, KAT6A, led to identification of an aryl sulfonohydrazide derivative (CTX-0124143) that inhibited KAT6A with an IC50 of 1.0 μM. Elaboration of the structure–activity relationship and medicinal chemistry optimization led to the discovery of WM-8014 (97), a highly potent inhibitor of KAT6A (IC50 = 0.008 μM). WM-8014 competes with acetyl-CoA (Ac-CoA), and X-ray crystallographic analysis demonstrated binding to the Ac-CoA binding site. Through inhibition of KAT6A activity, WM-8014 induces cellular senescence and represents a unique pharmacological tool.
18
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 858 citations · Full text